Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (92) clinical trials

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Phase

The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).

Phase

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Extended field or total nodal irradiation had been the gold standard for early stage follicular lymphoma for a long time in Germany. An involved field (IF) irradiation has been favored due to the toxicity of large field irradiation in other countries (e.g. USA). However, smaller irradiation fields have been accompanied ...

Phase

Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma

Study Drug Administration: Each study cycle is 28 days. You will receive obinutuzumab by vein over about 4-6 hours on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 2-6 and Cycle 8 and then every even-numbered cycle after that (Cycles 10, 12, 14, ...

Phase

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib ...

Phase

Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

PRIMARY OBJECTIVES: I. Overall response rate (ORR) of rituximab and pembrolizumab in relapsed/refractory follicular lymphoma (FL). II. Overall response rate (ORR) of rituximab and pembrolizumab in relapsed/refractory diffuse large B cell lymphoma (DLBCL). SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of the combination of rituximab and pembrolizumab, and ...

Phase

Pedometer Activity Monitoring After ASCT

Patient-reported outcome measures (PROMs) Cancer patients experience significant physical and psychosocial consequences of cancer and treatment which affect quality of life (QoL). These consequences may be under-recognized and under-treated in oncology practice, resulting in greater morbidity that is costly to patients and the health system. Patient-reported outcome measures (PROMs) are ...

Phase

"MIRO" Molecularly Oriented Immuno-radio-therapy

Stage I/IIA follicular lymphoma (FL) is considered a localized disease that can be adequately treated with radiotherapy alone. This strategy is recommended by the guidelines of the "Societ Italiana di Ematologia" (SIE) and of the "European Society for Medical Oncology" (ESMO) The accurate definition of the truly localised forms represents ...

Phase

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Follicular lymphomas FL has been traditionally approached either by an initial watch and wait policy in the asymptomatic patient, or with single agent treatments with the purpose of maintaining a good quality of life for a prolonged time. During the last decades, treatment strategies have changed due to the continuous ...

Phase

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Donors will undergo G-CSF mobilization of peripheral blood stem cells (PBSC) prior to undergoing two apheresis collections of hematopoietic progenitor cells (HPC,A) and one apheresis collection of therapeutic cell product of purified natural killer cells (TC-NK). The HPC products will be T-cell depleted (TCD) using the investigational CliniMACS device. CD34+ ...

Phase